UK Medicines Information
NICE issues draft guidance on pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer
Information type:
Media and commentaries
Source:
National Institute for Health and Care Excellence
Specialities:
Cancers | Ear, nose and throat disorders | Neurological disorders
Summary
DRAFT NICE guidance does not recommend pembrolizumab as an option for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a combined positive score (CPS) of 1 or more.
UKMi comment
NICE seeks further data to reconsider this decision if appropriate.
Related links: